Abstract
Omalizumab is currently approved for treatment of asthma and chronic idiopathic urticaria. Its mechanism of action involves the binding of free IgE in serum and preventing IgE binding to mast cells, preventing mast cell mediator release with the potential to treat mast cell disorders. Here we present a case of mast cell activation syndrome (MCAS) responding to treatment with omalizumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have